(Circulation. 1996;93:1796-1802.)
© 1996 American Heart Association, Inc.
Articles |
Cholesterol Lowering and the Use of Healthcare Resources
Results of the Scandinavian Simvastatin Survival Study
Correspondence to Dr Terje R. Pedersen, Cardiology Section, Medical Department, Aker Hospital, N 0514 Oslo, Norway.
Background Advances in the treatment of cardiovascular disease have increased costs; annual cardiovascular healthcare expenditure in the United States currently exceeds $100 billion. Physicians and third-party payers need to assess the economic impact of treatments that reduce cardiovascular morbidity and mortality.
Methods and Results The Scandinavian Simvastatin Survival Study is a randomized, double-blind, placebo-controlled trial in which simvastatin reduced the risk of death by 30% (P=.0003) over the median follow-up period of 5.4 years in patients with previous myocardial infarction or stable angina pectoris as a result of a 42% reduction in the risk of coronary deaths (P=.00001). In the present report, data prospectively collected from hospital admissions were analyzed to evaluate the impact of simvastatin on healthcare resource use and perform a cost-minimization analysis. In the placebo group (n=2223), there were 1905 hospitalizations (average duration, 7.9 days) for acute cardiovascular events or coronary revascularization procedures among 937 patients, whereas in the simvastatin group (n=2221), there were 1403 such hospitalizations (average duration, 7.1 days) among 720 patients (all differences, P<.0001). The corresponding number of hospital days was 15 089 and 9951 in the two groups, respectively (34% reduction, P<.0001). In the United States, the resulting reduction in hospitalization costs over the 5.4 years of the trial would be $3872 per patient, reducing the effective cost of simvastatin by 88% to $0.28 per day.
Conclusions In addition to reducing mortality and morbidity in coronary heart disease patients, simvastatin markedly reduces use of hospital services, thus offsetting most of its cost.
Key Words: cholesterol • prevention • coronary disease • drugs
This article has been cited by other articles:
 |
|
 |
|
  W. S. Weintraub, W. E. Boden, Z. Zhang, P. Kolm, Z. Zhang, J. A. Spertus, P. Hartigan, E. Veledar, C. Jurkovitz, J. Bowen, et al. Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 12 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N F Murphy, S Stewart, C L Hart, K MacIntyre, D Hole, and J J V McMurray A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew-Paisley study Heart, December 1, 2006; 92(12): 1739 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Weintraub, E. M. Mahoney, A. Lamy, S. Culler, Y. Yuan, J. Caro, S. Gabriel, S. Yusuf, and CURE Study Investigators Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation J. Am. Coll. Cardiol., March 15, 2005; 45(6): 838 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
 |
|
 T. Marshall and A. Rouse Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study BMJ, July 27, 2002; 325(7357): 197 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Goldman, K. A. Phillips, P. Coxson, P. A. Goldman, L. Williams, M. G. M. Hunink, and M. C. Weinstein The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yarzebski, F. Spencer, R. J. Goldberg, D. Lessard, and J. M. Gore Temporal Trends (1986-1997) in Cholesterol Level Assessment and Management Practices in Patients With Acute Myocardial Infarction: A Population-Based Perspective Arch Intern Med, June 25, 2001; 161(12): 1521 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Grover, M. Dorais, G. Paradis, J. G. Fodor, J. J. Frohlich, R. McPherson, L. Coupal, and H. Zowall Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines Can. Med. Assoc. J., November 1, 2000; 163(10): 1263 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Vicari, G. J. Wan, A. M. Aura, C. M. Alexander, L. E. Markson, S. M. Teutsch, and for the Simvastatin Combined Hyperlipidemia Regist Use of Simvastatin Treatment in Patients With Combined Hyperlipidemia in Clinical Practice Arch Fam Med, September 1, 2000; 9(9): 898 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grover, L. Coupal, H. Zowall, and M. Dorais Cost-Effectiveness of Treating Hyperlipidemia in the Presence of Diabetes : Who Should Be Treated? Circulation, August 15, 2000; 102(7): 722 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Frankel, S. Ebrahim, G. Davey Smith, and B. New The limits to demand for health care Commentary: An open debate is not an admission of failure BMJ, July 1, 2000; 321(7252): 40 - 45. [Full Text]
|
|
|
|
 |
|
 S. M. Haffner Is All Coronary Heart Disease Prevention in Type 2 Diabetes Mellitus Secondary Prevention? J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2108 - 2110. [Full Text]
|
|
|
|
|
|
L. Goldman, P. Coxson, M. G. M. Hunink, P. A. Goldman, A. N. A. Tosteson, M. Mittleman, L. Williams, and M. C. Weinstein The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines J. Am. Coll. Cardiol., September 1, 1999; 34(3): 768 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D M Pickin, C J McCabe, L E Ramsay, N Payne, I U Haq, W W Yeo, and P R Jackson Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Heart, September 1, 1999; 82(3): 325 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy, J. I. Cleeman, B. M. Rifkind, L. H. Kuller, and for the Coordinating Committee of the National Cho Cholesterol Lowering in the Elderly Population Arch Intern Med, August 9, 1999; 159(15): 1670 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gotto Jr Lipid-lowering therapy for the primary prevention of coronary heart disease J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2078 - 2082. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Grover, L. Coupal, S. Paquet, and H. Zowall Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease: Forecasting the Incremental Benefits of Preventing Coronary and Cerebrovascular Events Arch Intern Med, March 22, 1999; 159(6): 593 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
West of Scotland Coronary Prevention Study Group The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study J. Am. Coll. Cardiol., March 15, 1999; 33(4): 909 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Soumerai and D. Ross-Degnan Inadequate Prescription-Drug Coverage for Medicare Enrollees -- A Call to Action N. Engl. J. Med., March 4, 1999; 340(9): 722 - 728. [Full Text]
|
|
|
|
|
|
A. M. Gotto Jr and S. M. Grundy Lowering LDL Cholesterol : Questions From Recent Meta-Analyses and Subset Analyses of Clinical Trial DataIssues From the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council Meeting Circulation, March 2, 1999; 99 (8): e1 - e7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Gutstein and V. Fuster Pathophysiology and clinical significance of atherosclerotic plaque rupture Cardiovasc Res, February 1, 1999; 41(2): 323 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Jacobson, J. R. Schein, A. Williamson, and C. M. Ballantyne Maximizing the Cost-effectiveness of Lipid-Lowering Therapy Arch Intern Med, October 12, 1998; 158(18): 1977 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. McBride, H. G. Schrott, M. B. Plane, G. Underbakke, and R. L. Brown Primary Care Practice Adherence to National Cholesterol Education Program Guidelines for Patients With Coronary Heart Disease Arch Intern Med, June 8, 1998; 158(11): 1238 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade and R. O. Bonow Chronic Heart Failure in the United States : A Manifestation of Coronary Artery Disease Circulation, January 27, 1998; 97(3): 282 - 289. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gotto Jr Cholesterol Management in Theory and Practice Circulation, December 16, 1997; 96(12): 4424 - 4430. [Abstract] [Full Text]
|
|
|
|
|
|
D. B. Miller Secondary Prevention for Ischemic Heart Disease: Relative Numbers Needed to Treat With Different Therapies Arch Intern Med, October 13, 1997; 157(18): 2045 - 2052. [Abstract] [PDF]
|
|
|
|
|
|
P. C. Avila, L. Campeau, G. L. Knatterud, M. Domanski, D. B. Hunninghake, and The Post Coronary Artery Bypass Graft Trial Invest Prevention of Atherosclerosis in Coronary-Artery Bypass Grafts N. Engl. J. Med., June 19, 1997; 336(25): 1839 - 1840. [Full Text]
|
|
|
|
|
|
A. M. Garber and W. S. Browner Cholesterol Screening Guidelines : Consensus, Evidence, and Common Sense Circulation, March 18, 1997; 95(6): 1642 - 1645. [Full Text]
|
|
|
|
|
|
M. Johannesson, B. Jonsson, J. Kjekshus, A. G. Olsson, T. R. Pedersen, H. Wedel, and The Scandinavian Simvastatin Survival Study Group Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart Disease N. Engl. J. Med., January 30, 1997; 336(5): 332 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N.A. Tosteson, M. C. Weinstein, M. G.M. Hunink, M. A. Mittleman, L. W. Williams, P. A. Goldman, and L. Goldman Cost-Effectiveness of Populationwide Educational Approaches to Reduce Serum Cholesterol Levels Circulation, January 7, 1997; 95(1): 24 - 30. [Abstract] [Full Text]
|
|
|
|
 |
|
 Management of hyperlipidaemia DTB, December 1, 1996; 34(12): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D Byrne and S. H Wild Lipids and secondary prevention of ischaemic heart disease BMJ, November 23, 1996; 313(7068): 1273 - 1274. [Full Text]
|
|
|
|
|
|
A S Wierzbicki and T M Reynolds Full treatment of the costs and benefits is needed BMJ, November 2, 1996; 313(7065): 1143 - 1143. [Full Text]
|
|
|
|
|
|
J J V McMurray and C E Morrison Study greatly underestimates the cost effectiveness of statin treatment BMJ, November 2, 1996; 313(7065): 1142a - 1142. [Full Text]
|
|
|
|
|
|
S. M. Grundy and S. Rogers More on Pravastatin and Coronary Disease N. Engl. J. Med., October 17, 1996; 335(16): 1239 - 1240. [Full Text]
|
|
|
|
 |
|
 Simvastatin Cost-Effective in Lowering Cholesterol Journal Watch Cardiology, August 1, 1996; 1996(801): 10 - 10. [Full Text]
|
|
|
|
 |
|
 CHOLESTEROL-LOWERING THERAPY REDUCES USE OF HOSPITAL RESOURCES Journal Watch (General), June 4, 1996; 1996(604): 1 - 1. [Full Text]
|
|
|
|
|
|
S. Yusuf and S. Anand Cost of Prevention : The Case of Lipid Lowering Circulation, May 15, 1996; 93(10): 1774 - 1776. [Full Text]
|
|